Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Treatment with trabectedin monotherapy did not extend median overall survival (OS) in a prospective, open-label ...

Trabectedin, a promising drug derived from the sea squirt Ecteinascidia turbinata, has shown potential in combating cancers resistant to conventional treatments. However, its precise mechanism of ...

They are among 502 scientists, engineers and innovators recognized for their achievements Rutgers faculty elected to the ...

And as Lovell approaches three years, he’s realized how important it is for him to check goals off of his bucket list. One is ...

More information: Kook Son et al, Trabectedin derails transcription-coupled nucleotide excision repair to induce DNA breaks ...

Trabectedin is an anticancer medicine prescribed to treat advanced soft tissue sarcoma such as liposarcoma, a cancer of fat cells and leiomyosarcoma, a cancer of smooth muscle tissue.

as well as introducing trabectedin to the market in 2007, which improves outcomes for sufferers of the bone cancer sarcoma.

Advanced epithelial ovarian cancer, cancer of the fallopian tube and primary peritoneal cancer have a poor prognosis and a high rate of disease recurrence following primary therapy. Recurrent ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window In patients with non-muscle invasive bladder cancer (NMIBC ...

Future Oncol. 2012;8(9):1135-1147. Follow-up, initiation, execution and tailoring of treatment in case of recurrence of ovarian cancer have to take into account evidence-based guidelines and the ...